Skip to main content
SBFM logo

SBFM · Sunshine Biopharma Inc.

$1.67 -0.04 (-2.34%) At close · Jul 24
Market Cap
$8.31M
Shares
5.01M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$36.31M +4.1%
FY2025 Revenue FY2017–FY2025
Net Income
-$5.98M -16.4%
FY2025 Net Income FY2010–FY2025
Gross Margin
33.76% +3.2pp
FY2025 Gross Margin FY2019–FY2025
Operating Margin
-17.15% -0.5pp
FY2025 Operating Margin FY2019–FY2025
Diluted EPS
-$73.20 +97.9%
FY2024 Diluted EPS FY2021–FY2024
Operating Cash Flow
-$5.33M +57.4%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$35.49M $36.31M $34.87M $24.09M $4.35M $228.43K $71.41K $21.12K $0 $0
$23.79M $24.05M $24.2M $15.75M $2.65M $117.83K $25.85K $11.05K $0 $0
$11.71M $12.26M $10.67M $8.34M $1.7M $110.6K $45.56K $10.07K $0 $0
33.76% 30.6% 34.61% 39.04% 48.42% 63.8% 47.68%
$420.76K $604.31K $933.9K $1.86M $811.86K $672.21K $1728 $15.2K $12.8K $0 $32.79K $8657 $327K $137.4K $1829 $142.65K $0
$18.03M $18.48M $16.48M $13.12M $28.7M $2.55M $622.44K $651.71K $1.16M $857.19K $993.11K $781.99K $1.76M $1.94M $706.68K $556.2K $537.38K
$37.76K $77.01K $38.45K $58.92K $58.92K $13.77K $14.36K $6629 $60.73K $3772 $0
$332.07K $223.53K $149.15K $25.16K $12.74K $14.07K $13.77K $49.36K $6629 $60.73K $4251 $0
-$6.33M -$6.23M -$5.81M -$4.79M -$27M -$2.44M -$576.87K -$641.64K -$1.16M -$857.19K -$993.11K -$780.28K -$1.76M -$1.94M -$706.68K -$556.2K
-17.15% -16.67% -19.86% -621.33% -1068.24% -807.83% -3037.91%
-$5.89M -$5.59M -$4.64M -$26.98M -$2.43M -$562.81K -$627.86K -$1.11M -$850.56K -$932.38K -$776.03K -$1.76M
$0 $8774 $137.31K $39.41K $328.82K $168.11K $115.9K $143.46K $104.83K $34.73K $307.21K $140.92K $6455 $1272
$349.2K $273.29K $443.15K $674.42K $489.61K -$10M -$2.21M -$436.42K -$973.66K -$183.05K -$2.5M -$872.63K -$179.1K -$555.41K -$1272
-$5.98M -$5.95M -$5.37M -$4.11M -$26.51M -$12.44M
$61.77K $21.61K -$234.86K $395.17K $233.3K $0 $0
-$6.04M -$5.98M -$5.13M -$4.51M -$26.74M -$12.44M -$2.78M -$1.66M -$2.16M -$1.04M -$3.5M -$1.65M -$1.93M -$2.49M -$707.95K -$556.2K -$537.38K
-16.46% -14.72% -18.7% -615.44% -5444.41% -3898.74% -7860.85%
-$5.98M -$5.13M -$12.44M -$2.78M -$1.66M -$2.16M -$1.04M -$3.5M
-$5.58M -$5.21M -$6.66M -$3.97M -$26.56M -$12.46M -$2.78M -$1.66M -$2.16M -$1.04M -$3.5M -$1.65M -$1.93M
USD/shares -$14.40 -$73.20 -$3,513.60 -$35,200.00 -$95,200.00 -$54,600.00 -$3,000.00 -$14,200.00 -$400.00 -$200.00 -$200.00 -$600.00 -$800.00 -$200.00 -$400.00 -$400.00
USD/shares -$73.20 -$3,513.60 -$35,200.00 -$95,200.00
shares 415.71K 70.17K 1282.5 759.0434 130.6031 51.0241 546.6407 152.3404 2181.714 21.24K 6113.9455 3306.5829 2769.791 2488.7567 1544.0838 1492.7962
shares 70.17K 1282.5 759.0434 130.6031
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $3.68M in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
Drug Manufacturers - Specialty & Generic median 34.34×
P/E (TTM)
Drug Manufacturers - Specialty & Generic median 20.32×
Key facts CIK 1402328 CUSIP 867781809 13F (30d) 3 filings 3 filers Visit website Investor relations